Income Statement (TTM)
Zentalis Pharmaceuticals, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|
| Revenue | 41 | 41 | 41 | 67 | 27 | 27 |
| Change (%) | 0.00 | 0.00 | 66.24 | -60.16 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | ||||||
| Change (%) | ||||||
| % of Revenue | ||||||
| Gross Operating Profit | 41 | 41 | 41 | 67 | 27 | 27 |
| Change (%) | 0.00 | 0.00 | 66.24 | -60.16 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| SG&A | 59 | 65 | 63 | 87 | 82 | 74 |
| Change (%) | 10.30 | -2.07 | 37.24 | -5.92 | -10.14 | |
| % of Revenue | 144.89 | 159.81 | 156.50 | 129.20 | 305.06 | 274.12 |
| R&D | 191 | 196 | 186 | 168 | 145 | 125 |
| Change (%) | 2.99 | -5.06 | -9.97 | -13.31 | -14.29 | |
| % of Revenue | 469.90 | 483.96 | 459.45 | 248.82 | 541.34 | 464.00 |
| OpEx | 249 | 261 | 250 | 255 | 227 | 198 |
| Change (%) | 4.71 | -4.32 | 2.02 | -10.79 | -12.79 | |
| % of Revenue | 614.79 | 643.77 | 615.94 | 378.02 | 846.40 | 738.12 |
| Operating Income | -209 | -221 | -209 | -187 | -201 | -171 |
| Change (%) | 5.63 | -5.12 | -10.42 | 6.97 | -14.51 | |
| % of Revenue | -514.79 | -543.77 | -515.94 | -278.02 | -746.40 | -638.12 |
| Interest Expense | -23 | |||||
| Change (%) | ||||||
| % of Revenue | -84.40 | |||||
| Net Income | -219 | -195 | -179 | -166 | -224 | -163 |
| Change (%) | -11.08 | -7.90 | -7.50 | 35.18 | -27.39 | |
| % of Revenue | -539.70 | -479.92 | -442.02 | -245.96 | -834.49 | -605.93 |
Source: Capital IQ
